C. John | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where C. John is active.

Explore More

Publication

Featured researches published by C. John.

Journal of Hepatology | 2010

266 CLINICAL MARKERS OF THE METABOLIC SYNDROME ARE ASSOCIATED WITH HCV GENOTYPE 1 INFECTION AND ARE STRONG NEGATIVE PREDICTORS OF EARLY VIROLOGICAL RESPONSE

Elmar Jaeckel; E Zehnter; C. John; T. Lutz; W. Schmidt; R. Link; P. Geyer; G. Teuber; M. Stern; H.R. Bruch; K.H. Hey; R. Heyne; B. Moeller; G. Bellmann; A. Schober; S. Stoll; Michael P. Manns

266 CLINICAL MARKERS OF THE METABOLIC SYNDROME ARE ASSOCIATED WITH HCV GENOTYPE 1 INFECTION AND ARE STRONG NEGATIVE PREDICTORS OF EARLY VIROLOGICAL RESPONSE E. Jaeckel, E. Zehnter, C. John, T. Lutz, W. Schmidt, R. Link, P. Geyer, G. Teuber, M. Stern, H.R. Bruch, K.H. Hey, R. Heyne, B. Moeller, G. Bellmann, A. Schober, S. Stoll, M.P. Manns. Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Center of Gastroenterology, Dortmund, Center of Gastroenterology, Berlin, Infektiologikum, Frankfurt, MVZ-Aerzteforum Seestrasse Dres. C. Mayr / PD W. Schmidt, Berlin, Clinic for Internal Medicine, St. Josefs Hospital, Offenburg, Center of Gastroenterology, Huenfeld, IFS, Stresemannallee 3, Frankfurt/M, Center of Internal Medicine, Frankfurt, Center of Gastroenterology, Bonn, Center of Gastroenterology, Paderborn, Center of Gastroenterology and Livercenter, General Practice, Berlin, Center of Gastroenterology, Goettingen, Roche Pharma AG, Grenzach-Wyhlen, Germany E-mail: [email protected]

Journal of Hepatology | 2010

309 COMPARISON OF EFFICACY BETWEEN PEGINTERFERON ALFA-2A OR −2B PLUS RIBAVIRINE IN THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN DAILY ROUTINE: RESULTS FROM PRACTICE

T. Witthoeft; Stefan Mauss; D. Hueppe; C. John; R. Heyne; Bernd Moeller; R. Link; A. Herrmann; Axel Baumgarten; A. Dikopoulos; G. Teuber

309 COMPARISON OF EFFICACY BETWEEN PEGINTERFERON ALFA-2A OR −2B PLUS RIBAVIRINE IN THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN DAILY ROUTINE: RESULTS FROM PRACTICE T. Witthoeft, S. Mauss, D. Hueppe, C. John, R. Heyne, B. Moeller, R. Link, A. Herrmann, A. Baumgarten, A. Dikopoulos, G. Teuber. Center of Gastroenterology, Stade, Center for HIV and Hepatogastroenterology, Duesseldorf, Center for Gastroenterology, Herne, Center of Gastroenterology, Practice of Internal Medicine, Center of Gastroenterology and Livercenter, Berlin, Internal Medicin, St. Josefs-Krankenhaus, Offenburg, Internal Medicine II, Friedrich-Schiller-Universitaet, Jena, Klinik fuer Innere Medizin I, Universitaetsklinikum Ulm, Ulm, Interdisziplinares Facharztzentrum Sachsenhausen, Frankfurt/Main, Germany E-mail: [email protected]

Journal of Hepatology | 2014

P1147 OUTCOMES AND COSTS OF TREATING HEPATITIS C WITH PROTEASE INHIBITORS: RESULTS FROM A MULTI-CENTRE STUDY

Jona T. Stahmeyer; S. Rossol; F. Bert; A.M. Abdelfattah; Stefan Mauss; R. Heyne; C. John; Stefan Pape; A. Schober; G. Teuber; H.R. Bruch; E Zehnter; D. Hueppe; H. Pfeiffer-Vornkahl; U. Alshuth; Christian Krauth

Journal of Hepatology | 2013

908 REAL-WORLD EFFICACY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

Ulrich Spengler; A. Schober; C. John; H.R. Bruch; R. Heyne; C. Antoni; A. Herrmann; Eckart Schott; H. Steffens; H.-G. Hoerster; D. Hueppe; U. Alshuth; Stefan Mauss; Peter Buggisch

Journal of Hepatology | 2013

875 REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY

G. Moog; A. Schober; C. Antoni; H.R. Bruch; A. Herrmann; C. John; H. Steffens; M. Leuschner; Ulrich Spengler; Bernd Moeller; K. Isernhagen; D. Hueppe; U. Alshuth; Stefan Mauss

Journal of Hepatology | 2014

P1149 PHYSICIAN ADHERENCE TO AND EFFICACY OF TRIPLE THERAPY WITH TELAPREVIR (TVR) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN (PEGIFN/RBV) IN A REAL-LIFE SETTING

Stefan Mauss; Andreas Schober; C. John; T. Lutz; Gero Moog; H.R. Bruch; G. Teuber; S. Christensen; R. Heyne; Stefan Pape; U. Naumann; M. Roessle; W. Schiffelholz; H. Loehr; U. Alshuth; D. Hueppe

Journal of Hepatology | 2014

P1136 TRIPLE THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING: IS IT POSSIBLE TO ACHIEVE SVR RATES COMPARABLE TO PIVOTAL TRIALS?

Peter Buggisch; Andreas Schober; H.R. Bruch; C. Antoni; H. Loehr; A. Herrmann; H. Steffens; Gero Moog; J. Haessner; H.-G. Hoerster; C. John; H.-J. Schlueter; R. Link; R. Heyne; Ulrich Spengler; U. Alshuth; D. Hueppe

Journal of Hepatology | 2013

830 CHOLESTEROL LEVELS AND PRESENCE OF DIABETES PREDICT EARLY VIROLOGICAL RESPONSE TO TRIPLE THERAPY WITH TELAPREVIR, PEG-INTERFERON alfa-2a 180 μg AND RIBAVIRIN IN CHRONIC HEPATITIS C

E. Jaeckel; E Zehnter; C. John; R. Heyne; G. Teuber; W. Schiffelholz; S. Christensen; C. Antoni; S. Pape; M. Roessle; H. Loehr; S. Stoll; U. Alshuth; D. Hueppe; Stefan Mauss; Michael P. Manns

Journal of Hepatology | 2012

1139 VIRAL RESPONSE AT WEEK 2 AS A PREDICITIVE FACTOR FOR RVR IN CHRONIC HCV GENOTYPE 1 INFECTION TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV)

Stefan Mauss; T. Lutz; K. Boeker; R. Link; G. Moog; Albrecht Stoehr; Axel Baumgarten; C. John; R. Heyne; Christoph Eisenbach; W. Schiffelholz; G. Teuber; B. Weber; Eckart Schott; H. Hillenbrand; U. Alshuth; D. Hueppe; Peter Buggisch

Journal of Hepatology | 2012

1121 EARLY MARKERS OF METABOLIC SYNDROME ARE ASSOCIATED WITH DISTINCT HCV GENOTYPES, WHILE ABNORMAL GLUCOSE TOLERANCE SUBSTANTIALLY DECREASES THE LIKELIHOOD OF SVR

Elmar Jaeckel; E Zehnter; T. Lutz; A. Carlebach; R. Link; C. John; G. Teuber; W. Schmidt; H.R. Bruch; R. Heyne; P. Geyer; B. Weber; M. Stern; U. Naumann; Ulrich Spengler; Christoph Herold; Albrecht Stoehr; P. Sandow; S. Stoll; Michael P. Manns

Explore More